Eco Animal Health (LSE:EAH) has received confirmation from the United States Department of Agriculture’s (USDA) Center for Veterinary Biologics that field safety trial data for its ECOVAXXIN MS poultry vaccine meets the requirements needed to support US licensure.
The vaccine, developed to target Mycoplasma synoviae infections in poultry, was evaluated in more than 170,000 commercial laying pullets across three sites in the US Midwest.
The regulatory assessment represents a further step in the US approval process for ECOVAXXIN MS, with the company expecting marketing authorisation by the end of the year.
ECOVAXXIN MS is the first product developed through Eco Animal Health’s proprietary research and development pipeline and has already been launched commercially in the European Union.
The company is expanding its vaccine portfolio as part of a strategy to increase its geographic reach and develop preventive animal health products alongside its existing treatments.
Eco Animal Health’s principal product, Aivlosin, is an antibiotic used to treat respiratory and intestinal diseases in pigs and poultry. It is sold in more than 70 markets through the group’s established commercial network.
The UK-headquartered company employs more than 200 people worldwide and is investing in a self-funded research and development pipeline focused on vaccines and other preventive therapies.
The USDA’s confirmation relates specifically to the field safety trial data. US marketing authorisation remains pending.
Leave a Reply